Jason M. Hafron

2 weeks ago | targetedonc.com | Mark Tyson |Jason M. Hafron

The American Urological Association (AUA) 2025 Annual Meeting has kicked off, and for oncologists specializing in bladder cancer, several key presentations are offering compelling insights into potential shifts in treatment paradigms. Among the most eagerly awaited updates were findings from pivotal studies addressing both Bacillus Calmette Guérin (BCG)-naive and BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

2 weeks ago | urologytimes.com | Jason M. Hafron |Hannah Clarke

OpinionVideoApril 26, 2025Author(s):,In an interview with Urology Times®, Jason M. Hafron, MD, CMO, discusses his talk, “Barriers in Recruiting and Running Effective Clinical Trials in Independent Practices,” which was presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Hafron is the chief medical officer and director of clinical research at Michigan Institute of Urology.

1 month ago | urologytimes.com | Jason M. Hafron |Hannah Clarke

Artificial intelligence (AI) has become a disruptor in nearly every sector, including health care. In a recent interview with Urology Times®, Jason M. Hafron, MD, CMO, speculated on the various ways in which AI will improve urologic care in the coming years, noting that we’re “just at the tip of the iceberg.”He began by highlighting the recent commercialization of the first AI-based risk stratification tool, ArteraAI.

1 month ago | urologytimes.com | Jason M. Hafron |Hannah Clarke

The bladder cancer space saw an explosion of advancements last year. In a recent interview with Urology Times®, Jason M. Hafron, MD, CMO, of Michigan Institute of Urology, shared his thoughts on what is yet to come.